Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Saved in:
| Title: | Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. |
|---|---|
| Authors: | Rocconi, Rodney P.1 (AUTHOR), Monk, Bradley J.2 (AUTHOR), Walter, Adam3 (AUTHOR), Herzog, Thomas J.4 (AUTHOR), Galanis, Evanthia5 (AUTHOR), Manning, Luisa6 (AUTHOR), Bognar, Ernest6 (AUTHOR), Wallraven, Gladice6 (AUTHOR), Stanbery, Laura6 (AUTHOR), Aaron, Phylicia6 (AUTHOR), Senzer, Neil6 (AUTHOR), Coleman, Robert L.7 (AUTHOR), Nemunaitis, John1,6 (AUTHOR) jnemunaitis@gradalisinc.com |
| Source: | Gynecologic Oncology. Jun2021, Vol. 161 Issue 3, p676-680. 5p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00908258 |
|---|---|
| DOI: | 10.1016/j.ygyno.2021.03.009 |
